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CLINICAL/SCIENTIFIC NOTES OPEN ACCESS
GLUT1 deficiency
Retinal detrimental effects of gliovascular modulation
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Most patients with glucose transporter type 1 (GLUT1) deficiency syndrome (G1D) experience
anticonvulsant-refractory epilepsy and abnormal cognitive and motor development.1 Ninety
percent of patients withG1Dharbor a causative loss-of-functionmutation in the SLC2A1 gene; in
the others, brain fluorodeoxyglucose (FDG) PET can confirm the diagnosis.
G1D investigation has centered on the cerebral aspects of the disease, but extracerebral mani-
festations are plausible.1 The eye is a likely substrate: retinal GLUT1 sustains ocular glucose
transport based on its expression in Müller, vascular endothelial, and pigmentary epithelial cells.
Notably, GLUT1 is a target for diabetic retinopathy drugs.2,3 We describe retinal abnormalities in
a patient with G1D in the broader context of the plausible mechanisms and consequences of
retinal GLUT1 loss of function or therapeutic inhibition.
Case report
A 20-year-old woman with the common epileptic form of G1D reported subnormal visual acuity
uncorrectable with glasses and harbored a de novo pathogenic SLC2A1 variant (c.1454C>T;
P485L).1,4 The mutation introduced a dileucine motif in GLUT1 associated with clathrin re-
cruitment and excessive internalization of cell membrane GLUT1.5
Her visual acuity was 20/40 (OD) and 20/30 (OS) with no other obvious ocular abnormalities.
Optical coherence tomography (OCT) revealed retinal thinning in the posterior pole respecting
the fovea (figure 1, A and B) and absence of the interdigitation band peripherally with moderate
photoreceptor layer thinning (figure 1, C and D). Swept source OCT demonstrated significant
choroidal thickening (571 and 495 μm in the OD and OS, respectively; normal for age:
;330–400 μm). Retinal fundus autofluorescence (FAF) demonstrated hyperautofluorescence
outside the fovea and an unusual hyperautofluorescence in the central fovea (figure 1, E and F).
OCT-angiography (OCTA) showed a paucity of perimacular vessels (figure 1, G and H).
There were functional correlates to these findings, including multiple D-15 Farnsworth color
testing defects in the protan axis bilaterally and suppressed cone flicker amplitudes with normal
rod system electroretinography (ERG) responses (figure e-1, links.lww.com/NXG/A276). Re-
peat testing over 1 year was invariant.
Discussion
Our patient with G1D exhibited structural and functional retinal dysfunction. The retinal changes
were congruent across all imaging modalities: the retinal thinning noted on macular color
thickness maps correlated with the hyperautofluorescence on FAF and with the area of reduced
From the University of Kentucky College of Medicine (M.H.); Retina Associates of Kentucky (J.K.), Lexington; Rare Brain Disorders Program (J.M.P.), Department of Neurology and
Neurotherapeutics, Department of Physiology (J.M.P.), Department of Pediatrics (J.M.P.), Eugene McDermott Center for Human Growth & Development/Center for Human Genetics
(J.M.P.), The University of Texas Southwestern Medical Center, Dallas; and Ophthalmic Genetics Program (J.K., R.S.M.), Department of Ophthalmology, University of Kentucky,
Lexington.
Go to Neurology.org/NG for full disclosures. Funding information is provided at the end of the article.
The Article Processing Charge was funded by The GLUT1 Foundation.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading
and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. 1
vessel density on OCTA. Together with the thickened choroid
and decreased cone flicker, the simplest interpretation of our
findings is early onset photoreceptor degeneration.
In the retina, Glut1-mediated transport occurs across capil-
lary endothelial cells of the inner blood-retinal barrier and
the retinal pigment epithelium (RPE). This implies that our
patient’s de novo somatic (and therefore uniformly vascular
and glial because there is no reason to suspect mosaicism)
mutation exerts secondary consequences on neurons (which
are largely devoid of GLUT1). This likely stems from re-
duced glucose (or another mediator) flux across retinal cell
types.
Modest GLUT1 expression changes are functionally relevant:
increased renal GLUT1 has deleterious consequences in di-
abetic nephropathy.6 Conversely, GLUT1 small interfering
RNAs (siRNAs) reduce retinal glucose and ameliorate di-
abetic retinopathy, which is accompanied by reduced ERG
signal amplitude and outer nuclear layer thinning.3 This is
analogous to our patient’s diminished cone flicker amplitude
and retinal thickness. Furthermore, diabetic mice exhibit in-
creased RPE GLUT1 expression after prolonged exposure to
hyperglycemia and hypoxia. The resulting elevated RPE glu-
cose can be associated with impaired pigment epithelium-
derived (PEDF) secretion, leading to imbalanced vascular
endothelial growth factor (VEGF)/PEDF and stimulated
neovascularization.3 Our patient exhibited reduced capillary
density, which may reflect altered VEGF/PEDF release as in
diabetic retinopathy.
Some diabetic retinopathy therapies target GLUT1, in-
cluding angiotensin-converting enzyme inhibitors such as
captopril. This occurs, in part, via decreased retinal glucose
after the reduction of GLUT1-mediated glucose transport
(despite unaltered GLUT1 expression). Intraocular siRNA
diminishes GLUT1 expression in the inner blood-retinal
barrier of streptozotocin-diabetic mice and decreases retinal
glucose.3 Last, GLUT1 inhibition by forskolin or genistein in
diabetic mice leads to similar results. In all these contexts,
retinal glucose decreases after treatment, suggesting that
GLUT1 inhibition can counteract the end result of multi-
factorial diabetic retinopathy.
However, GLUT1 inhibition may be detrimental to photo-
receptor and RPE cells. In mice, reduction of RPE glucose
via GLUT1 knockout results in outer segment shortening,
photoreceptor cell death, and Müller cell activation. This
underscores the importance of near-constant GLUT1 ac-
tivity in the retina.7 Our findings suggest that these experi-
mental observations are likely relevant in humans,
suggesting that therapeutic GLUT1 inhibition may result in
undesired effects.
Conclusions
Our case demonstrates the contribution of nonneural GLUT1
to retinal cell (including photoreceptor) activity and vision.
Although diabetic retinopathy therapies that inhibit GLUT1
are plausible, this inhibition may be detrimental. This case
also illustrates the value of retinal assessment in G1D and in
those receiving GLUT1-related diabetes therapies.
Figure 1 Retinalmultimodal imaging in apatientwithGLUT1
deficiency
(A and B) Optical coherence tomography (OCT) total macular color thick-
nessmaps (in microns) showing marked retinal thinning (blue-purple area)
outside the fovea in the right and left eyes, respectively. (C andD)OCT b-scans
at the foveal centers demonstrate thickened retinal pigment epithelial layer
interdigitation bands (red arrows) only at the foveal centers; the bands dis-
appear in the periphery of the scans. (E and F) Wide-field fundus auto-
fluorescence (FAF) images of the right and left eye, respectively, showing
increased FAF in the perifoveal area corresponding to the area of retinal
thinning depicted in (A and B). Note that the fovea demonstrates subtle but
abnormal hyperautofluorescence centrally; this area normally shows hypo-
autofluorescence because of macular pigment AF blockage. (G and H) OCT
angiography (OCTA) of the superficial capillary plexus demonstrates de-
creased perimacular vessel density. (A–F) See figure e-2 (links.lww.com/NXG/
A276) for comparison of all images to those of a normal subject.
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